{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T22:10:11Z","timestamp":1748729411418,"version":"3.41.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["13\/01261"],"award-info":[{"award-number":["13\/01261"]}]}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.mehy.2015.12.016","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T06:20:56Z","timestamp":1450506056000},"page":"44-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Does the ADMA\/DDAH\/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?"],"prefix":"10.1016","volume":"87","author":[{"given":"Bego\u00f1a","family":"Quintana-Villamandos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Delgado-Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4\u20135","key":"10.1016\/j.mehy.2015.12.016_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000175819","article-title":"Left ventricular hypertrophy and mortality\u2013results from the Framingham Study","volume":"81","author":"Kannel","year":"1992","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.mehy.2015.12.016_b0010","first-page":"1352","article-title":"Effect of telmisartan on the regression of the left ventricular hypertrophy in the patients of essential hypertension","volume":"7","author":"Misra","year":"2013","journal-title":"J Clin Diagn Res"},{"issue":"12","key":"10.1016\/j.mehy.2015.12.016_b0015","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1097\/HJH.0b013e3283593029","article-title":"Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient","volume":"30","author":"Gosse","year":"2012","journal-title":"J Hypertens"},{"issue":"19","key":"10.1016\/j.mehy.2015.12.016_b0020","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment of hypertension","volume":"292","author":"Devereux","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mehy.2015.12.016_b0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/00004872-199510000-00003","article-title":"Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment","volume":"13","author":"Muiesan","year":"1995","journal-title":"J Hypertens"},{"issue":"12","key":"10.1016\/j.mehy.2015.12.016_b0030","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1073\/pnas.100127897","article-title":"Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy","volume":"97","author":"Friddle","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pcad.2006.02.001","article-title":"From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease","volume":"48","author":"Gradman","year":"2006","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.mehy.2015.12.016_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/157340310791162659","article-title":"The Role of Asymmetric Dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease","volume":"6","author":"Sibal","year":"2010","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/1319-2442.148718","article-title":"Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients","volume":"26","author":"El Shahawy","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2015.12.016_b0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2010.12.001","article-title":"The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats","volume":"54","author":"Wang","year":"2011","journal-title":"Vascul Pharmacol"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/11631590-000000000-00000","article-title":"Clinical pharmacokinetics and therapeutic efficacy of esmolol","volume":"51","author":"Wiest","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/hr.2012.191","article-title":"Early regression of left ventricular hypertrophy after treatment with esmolol in an experimental rat model of primary hypertension","volume":"36","author":"Quintana-Villamandos","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.mehy.2015.12.016_b0065","doi-asserted-by":"crossref","first-page":"531087","DOI":"10.1155\/2014\/531087","article-title":"Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity","volume":"2014","author":"Arnalich-Montiel","year":"2014","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0070","doi-asserted-by":"crossref","first-page":"H2702","DOI":"10.1152\/ajpheart.00836.2004","article-title":"Regression of pressure overload-induced left ventricular hypertrophy in mice","volume":"288","author":"Gao","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7\u20138","key":"10.1016\/j.mehy.2015.12.016_b0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1081\/CEH-200031978","article-title":"Early target organ damage and its reversibility: the heart","volume":"26","author":"Rosei","year":"2004","journal-title":"Clin Exp Hypertens"},{"issue":"8","key":"10.1016\/j.mehy.2015.12.016_b0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1751-7176.2009.00137.x","article-title":"Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?","volume":"11","author":"Nadour","year":"2009","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.mehy.2015.12.016_b0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/01.HYP.28.2.269","article-title":"Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis","volume":"28","author":"Brilla","year":"1996","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0090","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/01.hjh.0000358830.95439.e8","article-title":"Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats","volume":"27","author":"Simko","year":"2009","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.25.85","article-title":"Perindopril reverses myocyte remodeling in the hypertensive heart","volume":"25","author":"Onodera","year":"2002","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1536\/ihj.51.359","article-title":"Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats","volume":"51","author":"Ishimitsu","year":"2010","journal-title":"Int Heart J"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0105","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HJH.0b013e3280e126d5","article-title":"Fibroblast apoptosis precedes cardiomyocyte mass reduction during left ventricular remodeling in hypertensive rats treated with amlodipine","volume":"25","author":"Duguay","year":"2007","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.mehy.2015.12.016_b0110","first-page":"236","article-title":"Regression of left ventricular hypertrophy by a candesartan based regimen in clinical practice. The VIPE study","volume":"7","author":"Barrios","year":"2006","journal-title":"JRAAS"},{"issue":"11","key":"10.1016\/j.mehy.2015.12.016_b0115","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1253\/circj.CJ-09-0324","article-title":"Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients","volume":"73","author":"Komatsu","year":"2009","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1464-5491.2011.03383.x","article-title":"Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial","volume":"29","author":"Fogari","year":"2012","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jash.2010.09.003","article-title":"Importance of blood pressure control in left ventricular mass regression","volume":"4","author":"Miller","year":"2010","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"10.1016\/j.mehy.2015.12.016_b0130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0735-1097(97)00311-2","article-title":"Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial","volume":"30","author":"Papademetriou","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.mehy.2015.12.016_b0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.phrs.2004.10.010","article-title":"Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats","volume":"51","author":"Mougenot","year":"2005","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0140","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ejheart.2008.03.002","article-title":"Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats","volume":"10","author":"Nishio","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1291\/hypres.28.79","article-title":"Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and\/or the angiotensin II Type 1 receptor blocker under comparable blood pressure reduction","volume":"28","author":"Asai","year":"2005","journal-title":"Hypertens Res"},{"issue":"2\u20133","key":"10.1016\/j.mehy.2015.12.016_b0150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000103384","article-title":"Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction","volume":"80","author":"Barone","year":"2007","journal-title":"Pharmacology"},{"issue":"11","key":"10.1016\/j.mehy.2015.12.016_b0155","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.106.666016","article-title":"Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the reversal of ventricular remodeling with Toprol-XL (REVERT) trial","volume":"116","author":"Colucci","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0165","first-page":"630","article-title":"Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension","volume":"18","author":"Degirmenci","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.mehy.2015.12.016_b0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nrcardio.2009.229","article-title":"Hypertension: cardiac hypertrophy as a target of antihypertensive therapy","volume":"7","author":"Zanchetti","year":"2010","journal-title":"Nat Rev Cardiol"},{"year":"2012","series-title":"Efecto del bloqueo \u00e21 adren\u00e9rgico en la regresi\u00f3n precoz del remodelado ventricular. Estudio experimental en un modelo de rata hipertensa (thesis)","author":"Fern\u00e1ndez","key":"10.1016\/j.mehy.2015.12.016_b0175"},{"issue":"4","key":"10.1016\/j.mehy.2015.12.016_b0180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1742-7843.2009.00440.x","article-title":"Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat","volume":"105","author":"Loch","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.33549\/physiolres.930000.49.37","article-title":"The potential role of nitric oxide in the hypertrophic growth of the left ventricle","volume":"49","author":"Simko","year":"2000","journal-title":"Physiol Res"},{"issue":"6","key":"10.1016\/j.mehy.2015.12.016_b0190","first-page":"409","article-title":"Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide","volume":"90","author":"Dias Garc\u00eda","year":"2008","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"10.1016\/j.mehy.2015.12.016_b0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1152\/physiolgenomics.00156.2002","article-title":"Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy","volume":"14","author":"Cappola","year":"2003","journal-title":"Physiol Genomics"},{"issue":"4","key":"10.1016\/j.mehy.2015.12.016_b0200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1020706316429","article-title":"Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis","volume":"7","author":"Wollert","year":"2002","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.20452\/pamw.1222","article-title":"Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end-stage renal disease treated with hemodialysis","volume":"122","author":"Napora","year":"2012","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.mehy.2015.12.016_b0210","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2002.00437.x","article-title":"Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients","volume":"62","author":"Zoccali","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mehy.2015.12.016_b0215","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/HYPERTENSIONAHA.110.152959","article-title":"Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells","volume":"56","author":"Luo","year":"2010","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.mehy.2015.12.016_b0220","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.ATV.0000136656.26019.6e","article-title":"Asymmetric dimethylarginine produces vascular lesions in endotelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress","volume":"24","author":"Suda","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.mehy.2015.12.016_b0225","first-page":"562","article-title":"Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels","volume":"65","author":"Trocha","year":"2010","journal-title":"Pharmazie"},{"issue":"8","key":"10.1016\/j.mehy.2015.12.016_b0230","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1139\/Y07-073","article-title":"Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats","volume":"85","author":"Li","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.mehy.2015.12.016_b0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(03)01315-3","article-title":"Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion","volume":"462","author":"Oudot","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2015.12.016_b0240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.vph.2005.09.005","article-title":"Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells","volume":"44","author":"Jia","year":"2006","journal-title":"Vasc Pharmacol"},{"issue":"7","key":"10.1016\/j.mehy.2015.12.016_b0245","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/10715760600690329","article-title":"Radical scavenging and NO-releasing properties of selected beta-adrenoreceptor antagonists","volume":"40","author":"Szajerski","year":"2006","journal-title":"Free Radic Res"},{"issue":"3","key":"10.1016\/j.mehy.2015.12.016_b0250","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0003-4975(99)00809-7","article-title":"Nitric oxide-generating \u03b2-adrenergic blocker nipradilol preserves postischemic cardiac function","volume":"68","author":"Horimoto","year":"1999","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.mehy.2015.12.016_b0255","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.mehy.2007.08.028","article-title":"Dimethylarginine dimethylaminohydrolase (DDAH)-A critical regulator of hypertensive left ventricular hypertrophy?","volume":"70","author":"Bai","year":"2008","journal-title":"Med Hypotheses"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T21:37:10Z","timestamp":1748727430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987715004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":51,"alternative-id":["S0306987715004703"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2015.12.016","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the ADMA\/DDAH\/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2015.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}